Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates
Summary
Processa Pharmaceuticals' binding term sheet with Intact Therapeutics for PCS12852 expired without a definitive license agreement, ending the potential partnership.
Key Events
-
Material Agreement Termination
The binding term sheet dated June 17, 2025, with Intact Therapeutics regarding PCS12852 expired on February 12, 2026.
-
No Definitive License Agreement
A definitive license agreement for PCS12852 was not executed, nor was the related proposed amendment to the License Agreement with Yuhan Corporation.
-
No Further Obligations
Following the expiration, neither Processa Pharmaceuticals nor Intact Therapeutics has any additional obligations under the term sheet.
Analysis
Processa Pharmaceuticals announced the expiration of its binding term sheet with Intact Therapeutics for the drug candidate PCS12852. This means a definitive license agreement was not executed, effectively ending the potential partnership and development path for PCS12852 with Intact Therapeutics. For a micro-cap biotechnology company, the termination of a material agreement related to a drug candidate represents a significant setback, potentially impacting future development, funding, and revenue prospects for that asset.
At the time of this filing, PCSA was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $2.05 to $19.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.